Clinical Trials Logo

ARID1A Gene Mutation clinical trials

View clinical trials related to ARID1A Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05523440 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation

Start date: February 15, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the proportion of tumor response to the combination treatment with niraparib and bevacizumab and see what effects (good and bad) this combination treatment has on patients with recurrent endometrial or ovarian cancer with ARID1A mutation.

NCT ID: NCT05490472 Recruiting - Solid Tumors Clinical Trials

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

Start date: December 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

NCT ID: NCT05226507 Recruiting - Ovarian Cancer Clinical Trials

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Start date: December 31, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.

NCT ID: NCT05023655 Recruiting - Solid Tumor Clinical Trials

Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Start date: January 6, 2022
Phase: Phase 2
Study type: Interventional

The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in driving the biology of ARID1A mutated malignancies, we hypothesize that inhibition of EZH2 with tazemetostat will lead to significant clinical benefit in ARID1A mutated malignancies.